Ignite Creation Date:
2024-05-06 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05296278
Status:
RECRUITING
Last Update Posted:
2024-01-10
First Post:
2022-03-16
Brief Title:
Efficacy and Biomarker Explanation of IBI-323 Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Sponsor:
Organization:
Hunan Province Tumor Hospital